REVB Insider Trading

Insider Ownership Percentage: 19.90%
Insider Buying (Last 12 Months): $32,000.00
Insider Selling (Last 12 Months): $0.00

Revelation Biosciences Insider Trading History Chart

This chart shows the insider buying and selling history at Revelation Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Revelation Biosciences Share Price & Price History

Current Price: $0.25
Price Change: +0.30 (1.20%)
As of 10/5/2022 01:00 AM ET

This chart shows the closing price history over time for REVB up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Revelation Biosciences Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/25/2022George F TidmarshDirectorBuy20,000$1.60$32,000.00View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Revelation Biosciences (OTCMKTS:REVB)

5.38% of Revelation Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Revelation Biosciences Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/13/2022Ergoteles LLC22,327$25K0.0%N/A0.148%Search for SEC Filing on Google Icon
5/12/2022Monashee Investment Management LLC817,562$0.93M0.3%N/A5.420%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Revelation Biosciences logo
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
Read More on Revelation Biosciences

Today's Range

Now: $0.25
Low: $0.23
High: $0.27

50 Day Range

MA: $0.41
Low: $0.24
High: $0.60

52 Week Range

Now: $0.25
Low: $0.22
High: $11.29

Volume

320,799 shs

Average Volume

382,149 shs

Market Capitalization

$5.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Revelation Biosciences?

Revelation Biosciences' top insider investors include:
  1. George F Tidmarsh (Director)
Learn More about top insider investors at Revelation Biosciences.